Influence of formulation composition and processing on the content uniformity of low-dose tablets manufactured at kilogram scale Content uniformity of low-dose tablets D.G. Morris et al.

Daniel G. Morris, Brett F. Truitt, Angela Kong, Norma Leyva, Paul E. Luner

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The purpose of this study was to investigate the impact of processing, API loading, and formulation composition on the content uniformity of low-dose tablets made using direct compression (DC) and roller compaction (RC) methods at 1kg scale. Blends of 1:1 microcrystalline cellulose/lactose or 1:1 microcrystalline cellulose/dicalcium phosphate anhydrous with active pharmaceutical ingredient (API) at loadings of 0.2, 1 and 5% were processed either by DC or RC. A statistical analysis showed that DC produced comparable content uniformity results to RC. Microcrystalline cellulose/lactose formulations had improved average potency compared to microcrystalline cellulose/dicalcium phosphate anhydrous formulations for both DC and RC. The impact of segregation in the DC blends and adhesion to equipment surfaces was assessed to aid in understanding potency trends. DC may be as suitable as RC for low-dose regime (e.g.

Original languageEnglish (US)
Pages (from-to)451-460
Number of pages10
JournalPharmaceutical Development and Technology
Volume14
Issue number5
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Tablets
Lactose
Pharmaceutical Preparations
Equipment and Supplies
microcrystalline cellulose
phosphocellulose
anhydrous dibasic calcium phosphate

Keywords

  • Content uniformity
  • Direct compression
  • Dry granulation
  • Low-dose tablets
  • Segregationd

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Influence of formulation composition and processing on the content uniformity of low-dose tablets manufactured at kilogram scale Content uniformity of low-dose tablets D.G. Morris et al. / Morris, Daniel G.; Truitt, Brett F.; Kong, Angela; Leyva, Norma; Luner, Paul E.

In: Pharmaceutical Development and Technology, Vol. 14, No. 5, 2009, p. 451-460.

Research output: Contribution to journalArticle

@article{8b1b04b799e941e384e5155ebcb316fa,
title = "Influence of formulation composition and processing on the content uniformity of low-dose tablets manufactured at kilogram scale Content uniformity of low-dose tablets D.G. Morris et al.",
abstract = "The purpose of this study was to investigate the impact of processing, API loading, and formulation composition on the content uniformity of low-dose tablets made using direct compression (DC) and roller compaction (RC) methods at 1kg scale. Blends of 1:1 microcrystalline cellulose/lactose or 1:1 microcrystalline cellulose/dicalcium phosphate anhydrous with active pharmaceutical ingredient (API) at loadings of 0.2, 1 and 5{\%} were processed either by DC or RC. A statistical analysis showed that DC produced comparable content uniformity results to RC. Microcrystalline cellulose/lactose formulations had improved average potency compared to microcrystalline cellulose/dicalcium phosphate anhydrous formulations for both DC and RC. The impact of segregation in the DC blends and adhesion to equipment surfaces was assessed to aid in understanding potency trends. DC may be as suitable as RC for low-dose regime (e.g.",
keywords = "Content uniformity, Direct compression, Dry granulation, Low-dose tablets, Segregationd",
author = "Morris, {Daniel G.} and Truitt, {Brett F.} and Angela Kong and Norma Leyva and Luner, {Paul E.}",
year = "2009",
doi = "10.1080/10837450902832885",
language = "English (US)",
volume = "14",
pages = "451--460",
journal = "Pharmaceutical Development and Technology",
issn = "1083-7450",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Influence of formulation composition and processing on the content uniformity of low-dose tablets manufactured at kilogram scale Content uniformity of low-dose tablets D.G. Morris et al.

AU - Morris, Daniel G.

AU - Truitt, Brett F.

AU - Kong, Angela

AU - Leyva, Norma

AU - Luner, Paul E.

PY - 2009

Y1 - 2009

N2 - The purpose of this study was to investigate the impact of processing, API loading, and formulation composition on the content uniformity of low-dose tablets made using direct compression (DC) and roller compaction (RC) methods at 1kg scale. Blends of 1:1 microcrystalline cellulose/lactose or 1:1 microcrystalline cellulose/dicalcium phosphate anhydrous with active pharmaceutical ingredient (API) at loadings of 0.2, 1 and 5% were processed either by DC or RC. A statistical analysis showed that DC produced comparable content uniformity results to RC. Microcrystalline cellulose/lactose formulations had improved average potency compared to microcrystalline cellulose/dicalcium phosphate anhydrous formulations for both DC and RC. The impact of segregation in the DC blends and adhesion to equipment surfaces was assessed to aid in understanding potency trends. DC may be as suitable as RC for low-dose regime (e.g.

AB - The purpose of this study was to investigate the impact of processing, API loading, and formulation composition on the content uniformity of low-dose tablets made using direct compression (DC) and roller compaction (RC) methods at 1kg scale. Blends of 1:1 microcrystalline cellulose/lactose or 1:1 microcrystalline cellulose/dicalcium phosphate anhydrous with active pharmaceutical ingredient (API) at loadings of 0.2, 1 and 5% were processed either by DC or RC. A statistical analysis showed that DC produced comparable content uniformity results to RC. Microcrystalline cellulose/lactose formulations had improved average potency compared to microcrystalline cellulose/dicalcium phosphate anhydrous formulations for both DC and RC. The impact of segregation in the DC blends and adhesion to equipment surfaces was assessed to aid in understanding potency trends. DC may be as suitable as RC for low-dose regime (e.g.

KW - Content uniformity

KW - Direct compression

KW - Dry granulation

KW - Low-dose tablets

KW - Segregationd

UR - http://www.scopus.com/inward/record.url?scp=70350639588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350639588&partnerID=8YFLogxK

U2 - 10.1080/10837450902832885

DO - 10.1080/10837450902832885

M3 - Article

VL - 14

SP - 451

EP - 460

JO - Pharmaceutical Development and Technology

JF - Pharmaceutical Development and Technology

SN - 1083-7450

IS - 5

ER -